It is with great sadness that we announce the passing on 4 August of our highly respected and much loved colleague, Robert Davis. Our thoughts are with his wife Kathy and daughters Tamsin and Tara at this time. Wise, kind, warm, inspirational and a natural leader are all descriptions that capture the person Robert was … Continued
LONDON and DALLAS, Aug. 1, 2019 /PRNewswire/ UK headquartered ActiveOps Ltd, a leader in digital operations management solutions today announced the completion of its acquisition of OpenConnect Inc, headquartered in Dallas, Texas. The acquisition will enhance the capabilities of the Workware™ software suite by incorporating OpenConnect’s unique data capture technology. ActiveOps customers will gain new operations performance insights and automate data … Continued
Calculus Capital has beaten off tough competition to become a finalist in three categories; Best EIS Investment Manager, Best VCT Investment Manager and Growth Investor of the Year at the fifth Growth Investor Awards. For five years, these awards have shone a spotlight on the providers who have an impact beyond investment: creating jobs, boosting … Continued
Calculus has made four investments in July across sectors including medtech, software and technology. On 3 July Calculus closed investments in Arcis Biotechnology and Quai Administration Services. Arcis has developed a patent-protected platform technology which is seeking to improve the Molecular Diagnostics sector. Arcis’ technology allows the extraction of DNA and RNA from various sample types (human, … Continued
Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has signed a commercial distribution agreement with Opentrons, the developer of affordable pipetting robots. The agreement allows Opentrons to directly distribute Arcis’ sample preparation kits to laboratories globally, providing scientists with a complete, accessible and automated solution for high throughput RNA/DNA preservation … Continued
The immunotherapy specialist gave an update on progress for a ‘busy and productive’ half-year. More progress has been made towards beginning a Phase 1/2 clinical trial for Modi-1, the first cancer treatment from the company’s Moditope platform. The company will begin recruiting patients with advanced melanoma for UK Phase 2 clinical trials of its SCIB1 … Continued
Calculus Capital portfolio company C4X Discovery Holdings plc has teamed up with fellow UK-based biopharma, PhoreMost, to look for treatments for Parkinson’s Disease and other ‘undruggable’ diseases. The pair will take potentially useful compounds already identified by C4X’s Taxonomy 3 platform and run them through PhoreMost’s SITESEEKER screening platform. That data can then be exploited by … Continued
Global technology provider Avvio has upsized its London offices and is making a number of new appointments as it continues its impressive global growth. Located in the heart of the capital – nestled between Charing Cross and Leicester Square – Avvio’s new UK base is twice as big as the company’s previous residence and reflects … Continued
The UK Creative Content EIS Fund is now open for investment following the official launch event of the Fund on 10 June. Game of Thrones star Natalie Dormer, who spoke at the launch event, has hailed the launch of the BFI-associated UK Creative Content EIS Fund as “an important event for the UK screen industry”. … Continued
At a prestigious awards ceremony in the Banqueting House, Whitehall on Thursday 20th June, Calculus Capital were delighted to take home two awards. The first award was for our Chief Executive John Glencross, who picked up Outstanding Contribution to the EIS Industry by an Individual. Calculus Capital won Outstanding Contribution to EIS Investment Management by … Continued